Relevant bibliographies by topics / Vaccine discovery

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Vaccine discovery'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vaccine discovery.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Vaccine discovery"

1

Rappuoli, Rino, Steven Black, and Paul Henri Lambert. "Vaccine discovery and translation of new vaccine technology." Lancet 378, no. 9788 (July 2011): 360–68. http://dx.doi.org/10.1016/s0140-6736(11)60440-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Vaccine Discovery and Translation of New Vaccine Technology." Pediatric Infectious Disease Journal 30, no. 12 (December 2011): 1051. http://dx.doi.org/10.1097/inf.0b013e31822ec698.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rappuoli, Rino, Matthew J. Bottomley, Ugo D’Oro, Oretta Finco, and Ennio De Gregorio. "Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design." Journal of Experimental Medicine 213, no. 4 (March 28, 2016): 469–81. http://dx.doi.org/10.1084/jem.20151960.

Full text
Abstract:
Traditionally, vaccines have been developed by cultivating infectious agents and isolating the inactivated whole pathogen or some of its purified components. 20 years ago, reverse vaccinology enabled vaccine discovery and design based on information deriving from the sequence of microbial genomes rather than via the growth of pathogens. Today, the high throughput discovery of protective human antibodies, sequencing of the B cell repertoire, and the increasing structural characterization of protective antigens and epitopes provide the molecular and mechanistic understanding to drive the discovery of novel vaccines that were previously impossible. We are entering a “reverse vaccinology 2.0” era.
APA, Harvard, Vancouver, ISO, and other styles
4

Gautam, Manish, Sunil Gairola, Suresh Jadhav, and Bhushan Patwardhan. "Ethnopharmacology in vaccine adjuvant discovery." Vaccine 26, no. 41 (September 2008): 5239–40. http://dx.doi.org/10.1016/j.vaccine.2008.07.045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Weil, Alan R. "Vaccine Discovery, Production, And Delivery." Health Affairs 35, no. 2 (February 2016): 187. http://dx.doi.org/10.1377/hlthaff.2016.0051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Driguez, Patrick, Denise L. Doolan, Alex Loukas, Philip L. Felgner, and Donald P. McManus. "Schistosomiasis vaccine discovery using immunomics." Parasites & Vectors 3, no. 1 (2010): 4. http://dx.doi.org/10.1186/1756-3305-3-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tan, Swan, Andres Hazaet Gutiérrez, Phillip Charles Gauger, Tanja Opriessnig, Justin Bahl, Leonard Moise, and Anne Searls De Groot. "Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013–2017." Vaccines 9, no. 5 (May 6, 2021): 468. http://dx.doi.org/10.3390/vaccines9050468.

Full text
Abstract:
When swine flu vaccines and circulating influenza A virus (IAV) strains are poorly matched, vaccine-induced antibodies may not protect from infection. Highly conserved T cell epitopes may, however, have a disease-mitigating effect. The degree of T cell epitope conservation among circulating strains and vaccine strains can vary, which may also explain differences in vaccine efficacy. Here, we evaluate a previously developed conserved T cell epitope-based vaccine and determine the persistence of T cell epitope conservation over time. We used a pair-wise homology score to define the conservation between the vaccine’s swine leukocyte antigen (SLA) class I and II-restricted epitopes and T cell epitopes found in 1272 swine IAV strains sequenced between 2013 and 2017. Twenty-four of the 48 total T cell epitopes included in the epitope-based vaccine were highly conserved and found in >1000 circulating swine IAV strains over the 5-year period. In contrast, commercial swine IAV vaccines developed in 2013 exhibited a declining conservation with the circulating IAV strains over the same 5-year period. Conserved T cell epitope vaccines may be a useful adjunct for commercial swine flu vaccines and to improve protection against influenza when antibodies are not cross-reactive.
APA, Harvard, Vancouver, ISO, and other styles
8

Tuju, James, Gathoni Kamuyu, Linda M. Murungi, and Faith H. A. Osier. "Vaccine candidate discovery for the next generation of malaria vaccines." Immunology 152, no. 2 (July 24, 2017): 195–206. http://dx.doi.org/10.1111/imm.12780.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kocourkova, Aneta, Jan Honegr, Kamil Kuca, and Jana Danova. "Vaccine Ingredients: Components that Influence Vaccine Efficacy." Mini-Reviews in Medicinal Chemistry 17, no. 5 (February 1, 2017): 451–66. http://dx.doi.org/10.2174/1389557516666160801103303.

Full text
Abstract:
Vaccination is defined as the administration of an antigenic material in order to stimulate the immune system, leading to the development of adaptive immunity to a pathogen. Vaccines can prevent or reduce morbidity from a vast number of infections. This manuscript presents an analysis of vaccine types and vaccine substances, concentrating on individual components including the active ingredient, adjuvants, preservatives, stabilizers, inactivators, antibiotics, diluents and other substances. While many papers have been published on individual vaccine components, this review provides detail on a wide range of the most commonly-used vaccine ingredients and components that have been tested in clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
10

Li, Lu, Jian Wang, Stephen Nicholas, Elizabeth Maitland, Anli Leng, and Rugang Liu. "The Intention to Receive the COVID-19 Vaccine in China: Insights from Protection Motivation Theory." Vaccines 9, no. 5 (May 2, 2021): 445. http://dx.doi.org/10.3390/vaccines9050445.

Full text
Abstract:
(1) Background: More coronavirus disease 2019 (COVID-19) vaccines are gradually being developed and marketed. Improving the vaccination intention will be the key to increasing the vaccination rate in the future; (2) Methods: A self-designed questionnaire was used to collect data on COVID-19 vaccination intentions, protection motivation and control variables. Pearson Chi-square test and multivariate ordered logistic regression models were specified to analyze the determinants of intention to receive COVID-19 vaccine; (3) Results: Although the vaccine was free, 17.75% of the 2377 respondents did not want, or were hesitant, to receive the COVID-19 vaccine. Respondents’ cognition of vaccine safety, external reward and response efficacy were positively related to COVID-19 vaccination intention, while age, income and response cost were negatively related to the intention to receive the COVID-19 vaccine. Professionals and people without medical insurance had the lowest intention to vaccinate; (4) Conclusions: The older aged, people without health insurance, those with higher incomes and professionals should be treated as the key intervention targets. Strengthening publicity and education about the safety and efficacy of COVID-19 vaccines, training vaccinated people and community leaders as propagandists for the vaccine, and improving the accessibility to the COVID-19 vaccine are recommended to improve COVID-19 vaccination intention.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Vaccine discovery"

1

Huynh, Wally Chau. "Tumor antigens: From discovery to vaccine." Diss., The University of Arizona, 2001. http://hdl.handle.net/10150/290456.

Full text
Abstract:
Tumor specific antigens are the holy grails of cancer research. We made an attempt to identify novel tumor antigens by examining the tumor infiltrating B lymphocyte (TIL-B), and lymph node derived B cell (LN-B) population. TIL-B and LN-B cells were tested for reactivity against glutaraldehyde-fixed allogeneic cell lines by enzyme linked immunosorbant assay (ELISA). Of the 466 wells containing TIL-B cells, 29 (6.2%) of them produced antibodies that were reactive to allogeneic tumor cell lines. Of the 712 wells containing LN-B cells, 79 (11.1%) of them produced reactive antibodies to allogeneic tumor cell lines. Unfortunately, we were unable to identify specific clones producing those reactive antibodies by limiting dilution. Furthermore, we examined the murine immune response to a truncated p53 harboring four point mutations and fused to enhanced green fluorescent protein (EGFP). Balb/c mice were immunized with either plasmid DNA or the recombinant protein. We found that delivery by intramuscular injection of plasmid DNA encoding truncated, mutant p53 along with murine GM-CSF mice resulted in non-measurable antibody response and minimal cellular cytotoxic activity while recombinant protein immunization resulted in a strong antibody response and no measurable cytotoxic activity. We conclude that immunization with the fusion construct containing green fluorescent protein does not enhance cytotoxic responses to mutant p53. In addition, the creation of multiple point mutations in the p53 gene may have prevented the fusion protein from being processed and expressed on MHC class I molecules.
APA, Harvard, Vancouver, ISO, and other styles
2

Altindis, Emrah <1982&gt. "MetaVaccinology: a new vaccine discovery tool." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/3908/.

Full text
Abstract:
In the last decade, the reverse vaccinology approach shifted the paradigm of vaccine discovery from conventional culture-based methods to high-throughput genome-based approaches for the development of recombinant protein-based vaccines against pathogenic bacteria. Besides reaching its main goal of identifying new vaccine candidates, this new procedure produced also a huge amount of molecular knowledge related to them. In the present work, we explored this knowledge in a species-independent way and we performed a systematic in silico molecular analysis of more than 100 protective antigens, looking at their sequence similarity, domain composition and protein architecture in order to identify possible common molecular features. This meta-analysis revealed that, beside a low sequence similarity, most of the known bacterial protective antigens shared structural/functional Pfam domains as well as specific protein architectures. Based on this, we formulated the hypothesis that the occurrence of these molecular signatures can be predictive of possible protective properties of other proteins in different bacterial species. We tested this hypothesis in Streptococcus agalactiae and identified four new protective antigens. Moreover, in order to provide a second proof of the concept for our approach, we used Staphyloccus aureus as a second pathogen and identified five new protective antigens. This new knowledge-driven selection process, named MetaVaccinology, represents the first in silico vaccine discovery tool based on conserved and predictive molecular and structural features of bacterial protective antigens and not dependent upon the prediction of their sub-cellular localization.
APA, Harvard, Vancouver, ISO, and other styles
3

au, ngiles@anhb uwa edu, and Natalie Giles. "Exploitation of the Protein Tubulin For Controlling African Trypanosomiasis." Murdoch University, 2005. http://wwwlib.murdoch.edu.au/adt/browse/view/adt-MU20060315.191003.

Full text
Abstract:
This thesis presents the results of an investigation into the structural protein, tubulin, as a potential target for anti-trypanosomatid drug discovery and vaccine development. Recombinant alpha- and beta- tubulin proteins from Trypanosoma brucei rhodesiense were expressed as soluble fusion proteins in an E. coli expression system. The recombinant alpha- and beta- tubulins were used to determine the nature of binding of novel trifluralin analogues EPL-AJ 1003, 1007, 1008, 1016 and 1017. Native tubulin from rats was used to determine the extent of binding to mammalian tubulin. The results of this study clearly demonstrate two important aspects of the binding of trifluralins to tubulin. Firstly, they have specific affinity for trypanosomal tubulin compared with mammalian regardless of the chemical composition of the trifluralin analogue tested. Secondly, they have a demonstrably stronger affinity for alpha-tubulin compared with beta-tubulin. In addition, compounds 1007, 1008, 1016 and 1017 have strong binding affinities for alpha-tubulin, with limited binding affinity for mammalian tubulin, which indicates that these compounds selectively bind to trypanosomal tubulin. The morphology of bloodstream forms of T. b. rhodesiense exposed to trifluralin analogues was studied using electron microscopy and immunofluorescence to determine the ultrastructural changes these compounds induce as a result of binding to tubulin. All compounds tested induced severe irreparable damage in T. b. rhodesiense, including perturbation of subpellicular microtubules, extensive cytoplasmic swellings, axoneme and paraflagellar rod malformation, disconfiguration around the flagellar pocket and membrane disintegration. These results suggest that the mechanism of action of these trifluralin analogues is through the disruption of polymerization of tubulin into microtubules as a result of binding to alpha-tubulin. The potential for recombinant trypanosomal tubulins to be used as vaccine candidates was assessed by monitoring parasitaemia and length of survival of mice immunised with the proteins and challenged with a lethal infection of T. b. rhodesiense. Although all the mice vaccinated with recombinant tubulin developed a patent parasitaemia and did not survive, they were partially protected because their patency period and length of survival were significantly greater than the control groups. Furthermore, plasma collected from mice immunised with recombinant trypanosomal tubulin contained antibodies that recognized tubulin in a soluble extraction from T. b. rhodesiense. The results of this thesis confirm the potential for the structural protein, tubulin, to be used as a target for anti-trypanosomatid drug discovery and vaccine development.
APA, Harvard, Vancouver, ISO, and other styles
4

Romero, Saavedra Luis Félipe. "Systematic analysis of surface proteins in Enterococci : discovery of potential targets for vaccine development." Caen, 2015. http://www.theses.fr/2015CAEN2013.

Full text
Abstract:
Les entérocoques, couramment considérés comme membres de la flore microbienne du tractus gastro-intestinal, ont émergé comme agents pathogènes humains préoccupants au cours des dernières décennies. Leur virulence, principalement due à leur résistance innée et/ou acquise aux antibiotiques, nécessite la recherche de nouvelles thérapies alternatives pour y faire face. Du fait de leur rôle important dans les interactions de la cellule avec son environnement, les protéines de surface constituent une cible de choix pour les médicaments et le développement de vaccins, notamment à cause de leur capacité à interagir avec le system immunitaire de l’hôte. Dans la présente étude, nous avons identifié et caractérisé quelques protéines immunogènes de surface d’un isolat clinique d'Enterococcus faecium résistant à la vancomycine. Celles-ci sont évaluées comme des cibles potentielles pour le développement de vaccins. Les protéines candidates ont été identifiées aussi bien par trois méthodes différentes d’extraction de protéines de surface que par l’analyse de données transcriptomiques d’un modèle murin de péritonite. Huit protéines de surface ont été sélectionnées pour cette étude, dont six provenant des extractions protéiques (BML, DdcP, LysM, PBP5, PpiC and SCP) et deux (AdcAfm and PsaAfm) de l’analyse transcriptomique. Nous avons pu démontrer que les anticorps polyclonaux de lapin dirigés contre les protéines recombinantes purifiées induisent des anticorps opsoniques spécifiques qui conduisent à la mort de cinq isolats cliniques d’entérocoques. De plus, nous avons pu montrer que l’immunisation passive avec sept des sérums anti-protéines réduisait significativement la charge bactérienne d’E. Faecium E155 chez la souris. L’ensemble de nos résultats démontre que les antigènes protéiques analysés sont effectivement des candidats de vaccins prometteurs contre les infections à entérocoques. Ces résultats montrent également que les approches protéomique et transcriptomique peuvent être un moyen pour identifier de nouveaux antigènes protéiques
Enterococci, most commonly regarded as members of the microbial flora of the gastro intestinal tract, have emerged as human pathogens of significant concern in the last decades. Principally due to their innate and acquired resistance to antibiotics, the research for new therapeutic alternatives is needed. Surface proteins play important roles in bacterial interactions between the cell and its environment, making them ideal targets for drugs and vaccine development, mainly because of their ability to interact with the host immune system. In this study, we identified and characterized some of the immunogenic surface-related proteins present in a vancomycin-resistant Enterococcus faecium clinical isolate. The identified proteins were evaluated as potential targets for vaccine development. The protein candidates were identified either by three different surface protein extraction methods or by analysis of transcriptomic data from a mouse peritonitis model. We selected for this study eight surface related-proteins, six from the proteomic approaches (BML, DdcP, LysM, PBP5, PpiC and SCP) and two (AdcAfm and PsaAfm) from the transcriptomic analysis. We were able to demonstrate that rabbit polyclonal antibodies raised against the purified recombinant proteins induced specific opsonic antibodies that mediated killing of five enterococcal clinical strains. Furthermore, we showed that passive immunization with seven of the anti-protein sera significantly reduced the bacterial load of E. Faecium E155 in mice. Altogether, our results demonstrate the effectiveness of these protein antigens as promising vaccine candidates against enterococcal infections as well as the feasibility of these proteomic and transcriptomic approaches to identify novel protein antigens
APA, Harvard, Vancouver, ISO, and other styles
5

Jilesen, Zachary Keavin. "Discovery and Application of Neoepitopes in an Oncolytic Rhabdovirus Vaccine Approach to Treat Glioblastoma Multiforme." Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/39688.

Full text
Abstract:
Glioblastoma multiforme is the most common and lethal primary brain tumour in adults. Its aggressive and invasive phenotype makes it resistant to current standards of care, with a patient median survival following treatment of only 14 months. Potent and safe therapeutics are necessary to improve patient prognosis. Globally, efforts are being made in immunotherapies to combat such deleterious tumours. Preliminary work in the Stojdl lab has developed a novel oncolytic virus platform for brain cancer therapy that is non-toxic and exhibits potent anti-tumour efficacy. This platform is based on the rhabdovirus Farmington, identified for its potent oncolytic properties and engineering malleability. Herein, we begin to show our capability to discover and vaccinate against immunogenic neoepitopes derived from a mouse cancer mutanome. Engineering Farmington virus to express neoepitopes, allows for robust tumour specific immune proliferation following a prime vaccination. Overcoming problems of targeting self-antigen and antigen loss variants, a multi-neoepitope vaccine, presented here, is one of many alternative approaches to help combat cancer resistance. Despite achieving robust anti-tumour immunity by vaccination, selectivity of the tumour microenvironment remains an enormous challenge. Cumulative efforts in immunotherapy research will help drive novel therapeutics, like Farmington, into clinic and, ultimately, improve patient’s prognosis and quality of life.
APA, Harvard, Vancouver, ISO, and other styles
6

Pandya, Mital. "Definition of Bovine Leukocyte Antigen Diversity and Peptide Binding Profiles for Epitope Discovery." ScholarWorks @ UVM, 2016. http://scholarworks.uvm.edu/graddis/474.

Full text
Abstract:
The goal of the work presented herein was to further our understanding of Bovine Leukocyte Antigen (BoLA) class I diversity of Holstein cattle and develop tools to measure class I restricted T cell responses to intracellular pathogens such as foot and mouth disease virus (FMDV) following vaccination. BoLA is a highly polymorphic gene region that allows the bovine immune system to differentiate pathogen-infected cells from healthy cells. Immune surveillance by CD8+ T cells plays an important role in clearing viral infections. These CD8+ T cells recognize BoLA class I molecules bearing epitopes (antigenic peptides) of intracellular origin in their peptide binding groove. Polymorphisms in the peptide binding region of class I molecules determine affinity of peptide binding and stability during antigen presentation. Different antigen peptide motifs are associated with specific genetic sequences of class I molecules. In order to better understand the adaptive immune response mediated by BoLA molecules, technologies from human medicine such as high-throughput sequencing, biochemical affinity and stability assays, tetramers and IFN-γ ELIspot assays could be applied. Therefore, it was hypothesized that we can translate these technologies from the study of human T cell responses to the study of cattle immunity. The first objective was to establish a comprehensive method for genotyping BoLA of Holstein cattle by using Illumina MiSeq, Sanger sequencing and polymerase chain reaction sequence-specific primers (PCR-SSP) (See Chapter 2). This is an important first step in order to study the BoLA restricted immune responses following FMDV vaccination. The second objective was to define the FMDV capsid protein peptide repertoire bound by BoLA class I molecules using bioinformatics and biochemical affinity and stability assays to facilitate the identification of T cell epitopes (See Chapter 3). The third objective was to demonstrate clonal T cell expansion for specific epitope polypeptides using ex-vivo multi-color flow cytometric MHC-epitope complexes (tetramers), followed by IFN-γ production measured by an ELIspot assay to quantify and define the antigen specific response of Holstein cattle to FMDV vaccination (see Chapter 4). In this, my dissertation studies aimed to improve our understanding of the BoLA class I restricted T-cell responses to candidate FMDV vaccines in Holstein cattle. In this manner, my research will improve animal health through the production of assays for characterizing the bovine immune response to intracellular pathogens and enhance vaccine design leading to improved biologicals to protect cattle from devastating infectious diseases.
APA, Harvard, Vancouver, ISO, and other styles
7

Díaz, Varela Míriam. "Exploration of Extracellular Vesicles as a Novel Approach for Antigen Discovery and Vaccine Development against Plasmodium vivax Malaria." Doctoral thesis, Universitat de Barcelona, 2019. http://hdl.handle.net/10803/668981.

Full text
Abstract:
Plasmodium vivax is the most geographically widespread human malaria parasite. Research on this parasite needs to be expanded in order to develop adequate tools for its control such as a highly effective vaccine. One particular feature of P. vivax is its preference to invade immature red blood cells, also known as reticulocytes. Interestingly, ultrastructural studies performed on reticulocytes enabled the discovery of exosomes, extracellular vesicles (EVs) of endocytic origin. These vesicles were initially seen as a selective cargo-disposal pathway, but later works showed the involvement of exosomes, and other extracellular vesicles, in a variety of biological processes. Importantly, exosomes derived from reticulocytes infected with P. yoelii, a murine reticulocyte-prone parasite that resembles P. vivax, contained parasite proteins. When used in CpG-adjuvanted immunizations, exosomes were able to elicit long-lasting protective responses. This thesis hypothesizes that exosomes derived from P. vivax-infected reticulocytes contain parasite antigens and stimulate immune responses. We evaluated the potential of circulating extracellular vesicles from P. vivax infections as a source of antigens and as activators of T-cell responses, and explored human reticulocyte-derived exosomes as a vaccine platform against P. vivax malaria. We isolated EVs from plasma of P. vivax-infected patients and determined their protein composition by mass spectrometry-based proteomics in order to unveil their potential use in antigen discovery. We found parasite proteins associated to these vesicles that could serve as antigens. Indeed, two of the identified vivax proteins present promising cytotoxic T-cell epitopes as evidenced by in silico analysis. Moreover, we detected HLA class I molecules and observed an altered protein cargo in vesicles from vivax patients compared to healthy donors, thus suggesting that circulating EVs might affect the course of P. vivax infection. Next, we evaluated the in vitro interaction of these vesicles with leukocyte populations from the human spleen, given the importance of this organ in the induction of adaptative immune responses. Remarkably, we observed a significant interaction of monocytes, B-cells and T-cells with vesicles from patients compared to healthy individuals. We studied the capacity of these vesicles to activate T-cells, and preliminary results indicate that circulating vesicles from infections might stimulate CD8+ T-cell responses. Recent studies highlighted the role of cytotoxic CD8+ T-cell responses against P. vivax blood-stage parasites. In parallel, we studied the proteomic composition of exosomes derived from human reticulocytes and analyzed their ability to interact with antigen-presenting cells. We identified over 300 proteins in these vesicles, including HLA class I molecules, and found that these exosomes could be taken up by antigen-presenting cells, thus suggesting their contribution to the presentation of antigens. Collectively, our results indicate that EVs from vivax infections can be used in antigen discovery and might contribute to cell-mediated immune responses that could be critical for vivax control. In particular, reticulocyte-derived exosomes represent a potential vaccine platform to be furtherly explored. We believe this work has provided novel insights for vaccine development against P. vivax malaria.
Plasmodium vivax es el parásito que causa malaria humana más extendido geográficamente. Se ha de ampliar la investigación sobre este parásito para desarrollar herramientas adecuadas para su control, entre ellas, una vacuna altamente efectiva. Una característica particular de P. vivax es su preferencia por invadir glóbulos rojos inmaduros, también conocidos como reticulocitos. Curiosamente, estudios ultraestructurales realizados en reticulocitos permitieron el descubrimiento de exosomas, vesículas extracelulares (VEs) de origen endocítico. Los exosomas y otras vesículas extracelulares, fueron vistos inicialmente como una vía selectiva de eliminación de proteínas obsoletas, pero en la actualidad, se sabe que participan en una gran variedad de procesos biológicos. Los exosomas derivados de reticulocitos infectados con P. yoelii, un parásito propenso a invadir reticulocitos murinos que se asemeja a P. vivax, contienen proteínas parasitarias. Cuando estos exosomas se usan en inmunizaciones con adyuvante de CpG son capaces de provocar respuestas protectoras duraderas. Esta tesis plantea la hipótesis de que los exosomas derivados de reticulocitos infectados con P. vivax contienen antígenos del parásito y pueden estimular respuestas inmunes. Evaluamos el potencial de las VEs circulantes en infecciones de P. vivax como fuente de antígenos y como activadoras de respuestas de células T. Además, exploramos los exosomas derivados de reticulocitos humanos como una plataforma de vacunación contra la malaria vivax. Aislamos VEs del plasma de pacientes infectados con P. vivax y determinamos su composición proteica mediante proteómica basada en espectrometría de masas para investigar su potencial uso en el descubrimiento de antígenos. Encontramos proteínas del parásito asociadas a estas vesículas, las cuales podrían actuar como antígenos. De hecho, el análisis in silico de dos de estas proteínas reveló prometedores epítopos citotóxicos de células T. Además, detectamos moléculas HLA clase I y observamos un alterado contenido de proteínas en las vesículas de pacientes con vivax en comparación con donantes sanos, lo que sugiere que los VEs circulantes podrían afectar el curso de la infección por P. vivax. A continuación, evaluamos la interacción in vitro de estas vesículas con poblaciones leucocitarias del bazo humano, dada la importancia de este órgano en la inducción de respuestas inmunes adaptativas. Observamos una interacción significativamente elevada de monocitos, células B y células T con vesículas de pacientes en comparación con VEs de individuos sanos. Estudiamos la capacidad de estas vesículas para activar las células T, y los resultados preliminares indican que las vesículas circulantes de infecciones de vivax podrían estimular las respuestas de las células T CD8+. Recientes estudios han destacado el posible papel de las respuestas citotóxicas de las células T contra los parásitos de la etapa sanguínea de P. vivax. Paralelamente, analizamos la composición proteómica de los exosomas derivados de reticulocitos humanos y determinamos su capacidad para interactuar con células presentadoras de antígenos. Identificamos más de 300 proteínas en estas vesículas, incluidas las moléculas HLA de clase I, y descubrimos que estos exosomas podían ser internalizados por células presentadoras de antígenos, lo que sugiere su contribución a la presentación antigénica. En conjunto, nuestros resultados indican que las VEs de las infecciones por vivax pueden usarse en el descubrimiento de antígenos y pueden contribuir a respuestas inmunes mediadas por células que podrían ser críticas para el control de vivax. En particular, los exosomas derivados de reticulocitos representan una potencial plataforma de vacuna. Creemos que este trabajo ha proporcionado nuevas ideas para el desarrollo de vacunas contra la malaria por P. vivax.
APA, Harvard, Vancouver, ISO, and other styles
8

Di, Meo Giovanni. "Analisi delle comunità Twitter legate al tema dei vaccini." Master's thesis, Alma Mater Studiorum - Università di Bologna, 2018.

Find full text
Abstract:
La tesi consiste nella individuazione delle comunità più attive su Twitter sul tema "vaccini" e nella analisi della loro struttura, proprietà e comportamento. Le informazioni necessarie per condurre le analisi sono state estratte da Twitter tramite l'utilizzo del software R
APA, Harvard, Vancouver, ISO, and other styles
9

Yu, Chi Wang. "Discovery and characterization of the mechanisms of a vaccinia viral Bcl-2 homolog, F1L, on Inhibition of caspase-9 and NLRP1." Diss., [La Jolla] : University of California, San Diego, 2010. http://wwwlib.umi.com/cr/ucsd/fullcit?p3398745.

Full text
Abstract:
Thesis (Ph. D.)--University of California, San Diego, 2010.
Title from first page of PDF file (viewed May 5, 2010). Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
10

Ali, Rashid Majid Yousif. "Fragment-screening by X-ray crystallography of human vaccinia related kinase 1." Thesis, Linköpings universitet, Institutionen för fysik, kemi och biologi, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-166811.

Full text
Abstract:
Fragment-screening by X-ray crystallography (XFS) is an expensive and low throughput fragment drug discovery screening method, and it requires a lot of optimization for each protein target. The advantages with this screening method are that it is very sensitive, it directly gives the three-dimensional structure of the protein-fragment complexes, and false positives are rarely obtained. The aim of this project was to help Sprint Bioscience assess if the advantages with XFS outweigh the disadvantages, and if this method should be used as a complement to their differential scanning fluorimetry (DSF) screening method. An XFS campaign was run using the oncoprotein vaccinia related kinase 1 (VRK1) as a target protein to evaluate this screening method. During the development of the XFS campaign, a diverse fragment library was created which consisted of 298 fragments that were all soluble in DMSO at 1 M concentration. The crystallization of the protein VRK1 was also optimized in this project to get a robust, high throughput crystallization set up which generated crystals that diffracted at higher resolution than 2.0 Å when they were not soaked with fragments. The soaking protocol was also optimized in order to reduce both the steps during the screening procedure and mechanical stress caused to the crystals during handling. Lastly, the created fragment library was used in screening VRK1 at 87.5 mM concentration with XFS. 23 fragment hits could be obtained from the X-ray crystallography screening campaign, and the mean resolution of the crystal structures of the protein-fragment complexes was 1.87Å. 11 of the 23 fragment hits were not identified as hits when they were screened against VRK1 using DSF. XFS was deemed as a suitable and efficient screening method to complement DSF since the hit rate was high and fragments hits could be obtained with this method that could not be obtained with DSF. However, in order to use this screening method a lot of time needs to be spent in optimizing the crystal system so it becomes suitable for fragment screening. Sprint Bioscience would therefore need to evaluate the cost/benefit ratio of using this screening method for each new project.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Vaccine discovery"

1

Institute of Medicine (U.S.). Committee on the Review of Priorities in the National Vaccine Plan. Priorities for the national vaccine plan. Washington, DC: National Academies Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hargrove, Jim. The story of Jonas Salk and the discovery of the polio vaccine. Chicago: Childrens Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

N, Denoncourt Rena, and Warner Anjli C, eds. U.S. vaccine markets: Overview and four case studies. Washington, D.C: AEI Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bredeson, Carmen. Jonas Salk: Discoverer of the polio vaccine. Hillside, N.J: Enslow Publishers, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Development of vaccines: From discovery to clinical testing. Hoboken, N.J: John Wiley & Sons, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Flower, Darren R., and Yvonne Perrie, eds. Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-5070-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

New York Academy of Sciences. Pharmaceutical science to improve the human condition: Prix Galien 2011 : winners and finalist candidate of the Prix Galien USA Awards 2011. Malden, MA: Wiley Periodicals, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Harris, Duchess. The Discovery of the Polio Vaccine. Core Library, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Palatnik-de-Sousa, Clarisa Beatriz, Irene da Silva Soares, and Daniela Santoro Rosa, eds. Epitope Discovery and Synthetic Vaccine Design. Frontiers Media SA, 2018. http://dx.doi.org/10.3389/978-2-88945-522-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jonas Salk and the Polio Vaccine (Inventions and Discovery). Capstone Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Vaccine discovery"

1

Yero, Daniel, Oscar Conchillo-Solé, and Xavier Daura. "Antigen Discovery in Bacterial Panproteomes." In Vaccine Delivery Technology, 43–62. New York, NY: Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-0795-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Krishna, Sri, and Karen S. Anderson. "T-Cell Epitope Discovery for Therapeutic Cancer Vaccines." In Vaccine Design, 779–96. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3387-7_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kangueane, Pandjassarame. "MHC Informatics to Peptide Vaccine Design." In Bioinformation Discovery, 131–62. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-95327-4_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kangueane, Pandjassarame. "Cholera Toxin Analysis to Vaccine Design." In Bioinformation Discovery, 163–71. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-95327-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Beutler, Bruce. "Microbial Pathogenesis and the Discovery of Toll-Like Receptor Function." In Vaccine Adjuvants, 1–24. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59259-970-7_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gamazo, Carlos, and Juan M. Irache*. "Chapter 2.3. Nanostructures for Oral Vaccine Delivery." In Drug Discovery, 91–113. Cambridge: Royal Society of Chemistry, 2012. http://dx.doi.org/10.1039/9781849735292-00091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Slütter, Bram, and Wim Jiskoot*. "Chapter 3.3. Nanostructures for Nasal Vaccine Delivery." In Drug Discovery, 156–70. Cambridge: Royal Society of Chemistry, 2012. http://dx.doi.org/10.1039/9781849735292-00156.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Goodswen, Stephen J., Paul J. Kennedy, and John T. Ellis. "Computational Antigen Discovery for Eukaryotic Pathogens Using Vacceed." In Vaccine Delivery Technology, 29–42. New York, NY: Springer US, 2020. http://dx.doi.org/10.1007/978-1-0716-0795-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bennet, Jillian K. "From Scientific Discovery to Clinical Trial: Overcoming the Regulatory Hurdles — A Guide for Academic Researchers." In Vaccine Design, 187–96. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4899-0062-3_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Green, Luke R., Joseph Eiden, Li Hao, Tom Jones, John Perez, Lisa K. McNeil, Kathrin U. Jansen, and Annaliesa S. Anderson. "Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine." In Vaccine Design, 445–69. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3387-7_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Vaccine discovery"

1

King, B., JD Campbell, H. Salamon, RL Coffman, and EM Hessel. "Discovery of Novel Plasma Biomarkers for Monitoring Therapeutic Efficacy of Tolamba™, an Immunotherapeutic Vaccine for Ragweed Allergic Rhinitis." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2534.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mayer-Mokler, Andrea, Roberto Accolla, Yuk T. Ma, Regina Heidenreich, Francesco Izzo, Alfred Koenigsrainer, Markus Loeffler, et al. "Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant®): HEPAVAC." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-a043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ebeling, Régis, Carlos Córdova Sáenz, Jeferson Campos Nobre, and Karin Becker. "Quarenteners vs. Cloroquiners: a framework to analyze the effect of political polarization on social distance stances." In Symposium on Knowledge Discovery, Mining and Learning. Sociedade Brasileira de Computação, 2020. http://dx.doi.org/10.5753/kdmile.2020.11963.

Full text
Abstract:
The worldwide COVID-19 pandemic has struck people’s lives overnight. With an alarming contagious rate and no effective treatments or vaccines, it has evoked all sorts of reactions. In this paper, we propose a framework to analyze how political polarization affects groups’ behavior with opposed stances, using the Brazilian COVID polarized scenario as a case study. Two Twitter groups represent the pro/against social isolation stances referred to as Chloroquiners and Quarenteners. The framework encompasses: a) techniques to automatically infer from users political orientation, b) topic modeling to discover the homogeneity of concerns expressed by each group; c) network analysis and community detection to characterize their behavior as a social network group and d) analysis of linguistic characteristics to identify psychological aspects. Our main findings confirm that Cloroquiners are right-wing partisans, whereas Quarenteners are more related to the left-wing. The political polarization of Chloroquiners and Quarenteners influence the arguments of economy and life, and support/opposition to the president. As a group, the network of Chloroquiners is more closed and connected, and Quarenteners have a more diverse political engagement. In terms of psychological aspects, polarized groups come together on cognitive issues and negative emotions.
APA, Harvard, Vancouver, ISO, and other styles
4

Stafford, Phillip, Josh Richer, Stephen Albert Johnston, and Luhui Shen. "Abstract B35: Use of random peptide array to discover cancer neo-antigens for vaccines and diagnostics." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-b35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Stafford, Phillip, Josh Richer, Stephen Albert Johnston, and Luhui Shen. "Abstract PR10: Use of random peptide array to discover cancer neo-antigens for vaccines and diagnostics." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-pr10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Singh-Jasuja, Harpreet, Steffen Walter, Toni Weinschenk, Alexandra Kirner, Andrea Mayer-Mokler, Norbert Hilf, Oliver Schoor, et al. "Abstract SY27-03: Biomarker-guided development of novel multi-peptide cancer vaccines - from discovery to phase lll trials." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-sy27-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Huzayyin, O. A., M. S. El Morsi, M. A. Serag-Eldin, and M. F. El-Bedaiwy. "Prototype for Solar Powered Chip-Ice Production Facility." In ASME 2017 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/imece2017-72510.

Full text
Abstract:
Fishermen in highly isolated communities like Shallatin and Halayeb (Southern Egypt) suffer from the fouling of their catch before reaching the markets, due to the prevailing high ambient temperatures. Thus, they resort to block or crushed ice to cool their catch. Since fresh water is unavailable naturally, energy is needed to produce the fresh water from sea water, as well as to operate the chiller for ice production. Hence, employing solar energy as the sole source of energy for manufacturing ice, and producing the ice straight from saline water provides independence from both the electric grid and fresh water resources. A prototype solar powered facility for chip ice production from saline water has been designed, manufactured and erected in Shallatin for this purpose. The prototype, basically an ice production machine provides facilities for fish chilling and refrigeration compartments for vaccines, medicines and food products. The produced ice can be easily transported in to fishing boats in 10 kg plastic boxes that are easy to carry and handle. The prototype design employs many standard parts to cut costs and development time. Adequate ventilation with natural heat leakage to the cool surfaces of equipment (e.g. external surfaces of tanks and their piping) produces the desired room temperature without need for a fan coil unit, as discovered in actual implementation. The design should be applicable to all environments similar to Halayeb and Shellatin, which includes many places on the Red sea in the Gulf area and Africa. It is thus expected to be attractive for commercial exploitation in those places, and offers opportunities for local manufacturing and exportation of industrial products.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Vaccine discovery"

1

Altindis, E., R. Cozzi, B. Di Palo, F. Necchi, R. P. Mishra, M. R. Fontana, M. Soriani, et al. Protectome analysis: a new selective bioinformatics tool for bacterial vaccine candidate discovery. Cold Spring Harbor Laboratory, January 2014. http://dx.doi.org/10.1101/002089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Vaccine discovery' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography